253 related articles for article (PubMed ID: 21852131)
1. Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules.
Luker T; Alcaraz L; Chohan KK; Blomberg N; Brown DS; Butlin RJ; Elebring T; Griffin AM; Guile S; St-Gallay S; Swahn BM; Swallow S; Waring MJ; Wenlock MC; Leeson PD
Bioorg Med Chem Lett; 2011 Oct; 21(19):5673-9. PubMed ID: 21852131
[TBL] [Abstract][Full Text] [Related]
2. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
Buckley LA; Dorato MA
Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
[TBL] [Abstract][Full Text] [Related]
3. Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience.
Vanderwall DE; Yuen N; Al-Ansari M; Bailey J; Fram D; Green DV; Pickett S; Vitulli G; Luengo JI; Almenoff JS
Drug Discov Today; 2011 Aug; 16(15-16):646-53. PubMed ID: 21601652
[TBL] [Abstract][Full Text] [Related]
4. Computational toxicology--a tool for early safety evaluation.
Merlot C
Drug Discov Today; 2010 Jan; 15(1-2):16-22. PubMed ID: 19835978
[TBL] [Abstract][Full Text] [Related]
5. [Strategy of molecular drug design: hits, leads and drug candidates].
Guo ZR
Yao Xue Xue Bao; 2008 Sep; 43(9):898-904. PubMed ID: 19048779
[TBL] [Abstract][Full Text] [Related]
6. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
Meanwell NA
Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
[TBL] [Abstract][Full Text] [Related]
7. Review of the performance of the 3T3 NRU in vitro phototoxicity assay in the pharmaceutical industry.
Lynch AM; Wilcox P
Exp Toxicol Pathol; 2011 Mar; 63(3):209-14. PubMed ID: 20060695
[TBL] [Abstract][Full Text] [Related]
8. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
Kramer JA; Sagartz JE; Morris DL
Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
[TBL] [Abstract][Full Text] [Related]
9. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development.
Whitebread S; Hamon J; Bojanic D; Urban L
Drug Discov Today; 2005 Nov; 10(21):1421-33. PubMed ID: 16243262
[TBL] [Abstract][Full Text] [Related]
10. ADMET--Fifth Annual SMi Conference.
Comer JE
IDrugs; 2010 Sep; 13(9):610-4. PubMed ID: 20799141
[TBL] [Abstract][Full Text] [Related]
11. The value of in silico chemistry in the safety assessment of chemicals in the consumer goods and pharmaceutical industries.
Modi S; Hughes M; Garrow A; White A
Drug Discov Today; 2012 Feb; 17(3-4):135-42. PubMed ID: 22063083
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Pfizer compounds in EPA's ToxCast chemicals-assay space.
Shah F; Greene N
Chem Res Toxicol; 2014 Jan; 27(1):86-98. PubMed ID: 24328225
[TBL] [Abstract][Full Text] [Related]
13. Renal studies in safety pharmacology and toxicology: A survey conducted in the top 15 pharmaceutical companies.
Benjamin A; Gallacher DJ; Greiter-Wilke A; Guillon JM; Kasai C; Ledieu D; Levesque P; Prelle K; Ratcliffe S; Sannajust F; Valentin JP
J Pharmacol Toxicol Methods; 2015; 75():101-10. PubMed ID: 25637943
[TBL] [Abstract][Full Text] [Related]
14. Predictive toxicology: benchmarking molecular descriptors and statistical methods.
Feng J; Lurati L; Ouyang H; Robinson T; Wang Y; Yuan S; Young SS
J Chem Inf Comput Sci; 2003; 43(5):1463-70. PubMed ID: 14502479
[TBL] [Abstract][Full Text] [Related]
15. Toward in silico prediction of glass-forming ability from molecular structure alone: a screening tool in early drug development.
Mahlin D; Ponnambalam S; Höckerfelt MH; Bergström CA
Mol Pharm; 2011 Apr; 8(2):498-506. PubMed ID: 21344945
[TBL] [Abstract][Full Text] [Related]
16. Drug discovery: the leading edge.
Chapman T
Nature; 2004 Jul; 430(6995):109-15. PubMed ID: 15229608
[No Abstract] [Full Text] [Related]
17. Metabolomics in toxicology: preclinical and clinical applications.
Robertson DG; Watkins PB; Reily MD
Toxicol Sci; 2011 Mar; 120 Suppl 1():S146-70. PubMed ID: 21127352
[No Abstract] [Full Text] [Related]
18. Beyond profiling: using ADMET models to guide decisions.
Segall M; Champness E; Obrezanova O; Leeding C
Chem Biodivers; 2009 Nov; 6(11):2144-51. PubMed ID: 19937845
[TBL] [Abstract][Full Text] [Related]
19. A search to predict potential for drug-induced cardiovascular toxicity.
Hamlin RL
Toxicol Pathol; 2006; 34(1):75-80. PubMed ID: 16507547
[TBL] [Abstract][Full Text] [Related]
20. Lessons learned from candidate drug attrition.
Empfield JR; Leeson PD
IDrugs; 2010 Dec; 13(12):869-73. PubMed ID: 21154145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
